During the last session, CorMedix Inc (NASDAQ:CRMD)’s traded shares were 3.01 million, with the beta value of the company hitting 1.48. At the end of the trading day, the stock’s price was $7.16, reflecting an intraday loss of -2.45% or -$0.18. The 52-week high for the CRMD share is $13.85, that puts it down -93.44 from that peak though still a striking 49.58% gain since the share price plummeted to a 52-week low of $3.61. The company’s market capitalization is $434.45M, and the average intraday trading volume over the past 10 days was 2.59 million shares, and the average trade volume was 1.31 million shares over the past three months.
CorMedix Inc (CRMD) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CRMD has a Sell rating from 1 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.19.
CorMedix Inc (NASDAQ:CRMD) trade information
CorMedix Inc (CRMD) registered a -2.45% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.45% in intraday trading to $7.16, hitting a weekly high. The stock’s 5-day price performance is -34.73%, and it has moved by -30.42% in 30 days. Based on these gigs, the overall price performance for the year is 82.65%. The short interest in CorMedix Inc (NASDAQ:CRMD) is 8.18 million shares and it means that shorts have 10.23 day(s) to cover.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 20.44% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $9 respectively. As a result, CRMD is trading at a discount of -25.7% off the target high and -25.7% off the low.
CorMedix Inc (CRMD) estimates and forecasts
In the rating firms’ projections, revenue will increase 187.19% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 32.2M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 25.91M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 29.80%. While earnings are projected to return 284.29% in 2025.
CRMD Dividends
CorMedix Inc is due to release its next quarterly earnings on 2025-Mar-24. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
CorMedix Inc (NASDAQ:CRMD)’s Major holders
CorMedix Inc insiders own 1.25% of total outstanding shares while institutional holders control 40.00%, with the float percentage being 40.51%. BLACKROCK INC. is the largest shareholder of the company, while 164.0 institutions own stock in it. As of 2024-06-30, the company held over 3.55 million shares (or 6.167% of all shares), a total value of $15.39 million in shares.
The next largest institutional holding, with 2.9 million shares, is of VANGUARD GROUP INC’s that is approximately 5.0476% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.57 million.
